This is the first study to elucidate the dynamic alterations in the differentiation and functional impairment of CD8+ T cells during AML treatment, facilitating advancements in the understanding of CD8+ T cell dysfunction in AML. The gene discussed is CD8A; the disease is acute myeloid leukemia.